IYIgor S. Yavelov

Igor S. Yavelov

*This is an algorithmically generated author record based on publicly available information.

Igor S. Yavelov has a total of 519 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of the furosemide dose titration in the first day of treatment for decompensated chronic heart failure using urine output or urine sodium concentration monitoring

    by Ch. N. Sharapudinova, I. S. Yavelov, V. I. Vechоrko, O. V. Averkov, A. S. Samorukova, M. V. Yarygina, T. V. Duduk, O. M. Drapkina

    Aim . To compare the efficacy and safety of furosemide dose titration during the first 24 hours of treatment for decompensated heart failure (HF) with fluid retention, based on either urine volume or spot urinary sodium concentration. Material and methods. This prospective, randomised, open-label, single-center study included 110 patients with decompensated HF, signs of fluid retention, and regular furosemide use. The initial intravenous furosemide dose was twice the outpatient dose. In the first group (n=55), efficacy was assessed by 6-hour urine output: if ≥100 mL/h, the same dose was repeated after 12 hours; if response was insufficient, the dose was doubled every 6 hours until the target urine volume was achieved. In the second group (n=55), the 2-hour spot urinary sodium concentration was used: if ≥50 mmol/L, the same dose was repeated after 12 hours; if Results . Mean patient age was 74±9.2 years; male proportion was 52.7%. The median intravenous furosemide dose in the first 24 hours was 160 mg in the urine sodiumguided group versus 80 mg in the urine volumeguided group (pConclusion . In patients hospitalised with decompensated HF, furosemide dose titration during the first 24 hours based on urinary sodium concentration (compared to the urine volumebased approach) was associated with the use of higher doses, leading to greater weight loss, better congestion relief, an

  • Open Access

    Consensus statement on the results of the interdisciplinary expert council meeting with international participation on personalized prescription of hormone replacement therapy/menopausal hormone therapy in women at different age period

    by V. E. Balan, S. V. Yureneva, M. I. Yarmolinskaya, E. N. Andreeva, O. M. Drapkina, I. I. Baranov, A. L. Hirschberg, A. Cano, S. A. Berns, I. S. Yavelov, et al.

    A significant decrease in estrogen levels due to the onset of menopause is the cause of the development of clinically significant symptoms of climacteric syndrome, which significantly impair the quality of life, and also refers to factors that increase long-term cardiometabolic risks. According to the current Russian clinical recommendations, menopausal hormone therapy (MHT) is considered as the most effective method for the correction of climacteric disorders. An Interdisciplinary Expert Council was convened in the last quarter of 2025 to study the topical issues of managing patients in the peri-and postmenopausal periods and the specifics of prescribing MHT in various clinical situations, the main task of which was to optimize scientifically based algorithms for the management of patients with climacteric/postovariectomy syndromes. Based on the results of work by national and international specialists representing various fields of medicine, a consensus document was approved regulating the principles for prescribing HRT/MHT to women with concomitant somatic pathology.

  • Open Access

    Follow-up of patients with interstitial lung diseases by a primary care physician. Guidelines

    by O. M. Drapkina, S. N. Avdeev, I. V. Bukhtiyarov, M. I. Smirnova, M. Yu. Kryakova, R. N. Shepel, V. A. Nevzorova, I. A. Viktorova, L. Yu. Drozdova, P. V. Ipatov, et al.

    Interstitial lung diseases are a heterogeneous group of pathologies, the most common of which is idiopathic pulmonary fibrosis. The causes of interstitial diseases often remain unknown, but their pathogenesis is based on the gradual replacement of normal lung tissue with fibrous tissue. More than half of patients with interstitial lung diseases experience fibrosis progression, worsening symptoms, and the onset of respiratory failure within 2 years of diagnosis. Early diagnosis and timely follow-up are the primary means of disease management, particularly for idiopathic pulmonary fibrosis. This includes slowing disease progression, reducing the frequency and severity of exacerbations, and reducing the risk of developing and progressing different acute and chronic conditions that can affect respiratory symptoms and the prognosis of interstitial lung diseases. These guidelines are intended for primary care physicians, general practitioners, nurses working with these physicians, and paramedics at primary care facilities performing the doctor functions, including conducting outpatient follow-up. These guidelines are also intended for specialists such as pulmonologists, allergists/ immunologists, and other specialists involved in the care of patients with interstitial lung diseases. In addition, these guidelines are intended for heads of healthcare facilities (or its divisions) providing primary care, as well as students, residents, and postgraduate students at medical and pharmaceutical educational institutions.

  • Open Access

    Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG

    by E. V. Shlyakhto, I. I. Dedov, V. N. Serov, G. T. Sukhikh, G. P. Arutyunov, I. A. Suchkov, O. M. Drapkina, O. N. Tkacheva, Ya. A. Orlova, I. I. Baranov, et al.

    Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice

  • Open Access

    Outpatient monitoring of patients with stable coronary artery disease by a primary care physician. Guidelines

    by O. M. Drapkina, S. A. Boytsov, R. N. Shepel, I. V. Atyunina, L. I. Dezhurny, L. Yu. Drozdova, P. V. Ipatov, A. M. Kalinina, M. M. Lukyanov, S. Yu. Martsevich, et al.

    These guidelines describe the management of outpatient monitoring of patients with stable coronary artery disease by a general practitioner and include modern approaches to diagnosis — clinical and paraclinical methods — as well as treatment and prevention of complications. These guidelines will enable physicians to make informed clinical decisions within outpatient monitoring for patients with stable coronary artery disease based on the related algorithm presented (examinations, consultations). The guidelines are intended for general practitioners, family doctors, as well as for mid-level health providers working with the above-mentioned doctors, for paramedics performing the doctor functions regarding organizing and conducting outpatient follow-up. These guidelines can be used by healthcare executives, heads of primary care facilities, and their departments.


  • Relationship between chronic heart and venous insufficiency: possible mechanisms and clinical research findings

    by Yu.A. Pankrashina, I.S. Yavelov, K.A. Kaperiz, A.O. Rastatueva

    Chronic venous insufficiency (CVI) of the lower extremities is common and was once considered a localized disease. Recent evidence shows systemic effects of CVI, especially its link to the onset and progression of chronic heart failure (CHF). Objective. To characterize the possible relationships between chronic venous insufficiency of the lower extremities and chronic heart failure, to analyze the pathophysiological mechanisms of their interaction, as well as the role of chronic venous insufficiency of the lower extremities as a predictor of the development and progression of chronic heart failure. Materials and methods. The article reviews publications indicating a possible relationship between CVI and CHF. Sources were identified by searching the PubMed, eLibrary, and Google Scholar databases. Articles available in full-text, published from 2006 to 2025, were selected. Results. CVI has been shown to be associated with an increased risk of CHF, mortality, and adverse cardiovascular outcomes. Venous congestion and right heart dysfunction induce endothelial dysfunction, inflammation, and myocardial remodeling, forming a vicious circle. Conclusion. The accumulated data indicate that chronic venous insufficiency of the lower extremities and chronic heart failure are interrelated, and their combination worsens the prognosis. Further research is needed to clarify the mechanisms underlying the cause-and-effect relationship and to develop a comprehensive therapy.

  • Open Access

    Menopausal hormone therapy in patients with cardiovascular and metabolic diseases: an interdisciplinary Delphi consensus among Russian gynecologists, cardiologists, endocrinologists, gerontologists and geriatricians, phlebologists, and clinical pharmacologists

    by Gennadii T. Sukhikh, Vladimir N. Serov, Evgeny V. Shlyakhto, Ivan I. Dedov, Gregory P. Arutyunov, Olga N. Tkacheva, Antonina A. Smetnik, Igor A. Suchkov, Igor I. Baranov, Marina V. Shestakova, et al.

    More than one million women in Russia enter menopause each year. The severe estrogen deficiency associated with this transition causes symptoms that significantly impair quality of life and contribute to an increased risk of cardiovascular and metabolic diseases. Menopausal hormone therapy (MHT) is the established standard of care for menopausal symptoms. On the initiative of several professional societies (the Russian Society of Obstetricians and Gynecologists, the Russian Society of Cardiology, the Russian Association of Endocrinologists, the Eurasian Association of Therapists, the Russian Society of Gynecological Endocrinology and Menopause, the Russian Association of Gerontologists and Geriatricians, the Association of Phlebologists of Russia), a Delphi panel was convened to develop a multidisciplinary expert consensus on MHT for patients with cardiovascular and metabolic diseases. The goal was to enhance research and clinical approaches to managing menopausal women. A consensus was reached at the end of the first Delphi round. The experts agreed that initiating MHT requires a thorough assessment of individual risks, including cardiovascular health and comorbidities. MHT can offset metabolic and cardiovascular risk factors in peri- and postmenopausal women by normalizing the lipid profile, improving carbohydrate metabolism, and reducing insulin resistance. An interdisciplinary approach allows for personalized MHT, minimizes potential complications, improves the quality of life for peri- and postmenopausal women, and promotes active longevity.


  • Open Access

    "School" for patients with atrial fibrillation. Guidelines

    by Oxana M. Drapkina, Sergey A. Boytsov, Evgeny V. Shlyakhto, Evgeny G. Kamkin, Ekaterina V. Karakulina, Ekaterina D. Savchenko, Lyubov Yu. Drozdova, Anna M. Kalinina, Ruslan N. Shepel, Igor S. Yavelov, et al.

    Школа для больных с фибрилляцией предсердий. Методические рекомендации


  • Open Access

    "School" for patients with heart failure. Guidelines

    by Oxana M. Drapkina, Sergey A. Boytsov, Evgeny V. Shlyakhto, Evgeny G. Kamkin, Ekaterina V. Karakulina, Ruslan N. Shepel, Maria E. Zharova, Lyubov Yu. Drozdova, Anna M. Kalinina, Ekaterina D. Savchenko, et al.

    Школа для больных с сердечной недостаточностью. Методические рекомендации


  • Open Access

    "School" for patients with hypertension. Guidelines

    by Oxana M. Drapkina, Sergey A. Boytsov, Evgeny V. Shlyakhto, Evgeny G. Kamkin, Ekaterina V. Karakulina, Maria E. Zharova, Lyubov Yu. Drozdova, Anna M. Kalinina, Ekaterina D. Savchenko, Ruslan N. Shepel, et al.

    Школа для больных с артериальной гипертензией. Методические рекомендации